LOS ANGELES--(BUSINESS WIRE)--A patient at The Angeles Clinic and Research Institute is the first to enter a global, pivotal Phase 3 clinical trial for treating advanced melanoma. The experimental drug, Elesclomol, attacks cancer in an entirely new way and has shown promise in treating metastatic melanoma, delaying progression of the disease and possibly prolonging the lives of patients.
